Silvia Zucchini

Heparan sulfate proteoglycan binding by herpes simplex virus type 1 glycoproteins B and C, which differ in their contributions to virus attachment, penetration, and cell-to-cell spread.

Involvement of the neuropeptide nociceptin/orphanin FQ in kainate seizures.

Neuroprotective activity of CHF3381, a putative N-methyl-D-aspartate receptor antagonist.

Pro-nociceptin/orphanin FQ and NOP receptor mRNA levels in the forebrain of food deprived rats.

Delayed epileptogenesis in nociceptin/orphanin FQ-deficient mice.

Mechanisms of action of CHF3381 in the forebrain.

Pharmacological profile of nociceptin/orphanin FQ receptors regulating 5-hydroxytryptamine release in the mouse neocortex.

Immunotherapeutic activity of a recombinant combined gB-gD-gE vaccine against recurrent HSV-2 infections in a guinea pig model.

Alterations in seizure susceptibility and in seizure-induced plasticity after pharmacologic and genetic manipulation of the fibroblast growth factor-2 system.

Blockade of nociceptin/orphanin FQ transmission attenuates symptoms and neurodegeneration associated with Parkinson's disease.

Endogenous nociceptin/orphanin FQ signalling produces opposite spinal antinociceptive and supraspinal pronociceptive effects in the mouse formalin test: pharmacological and genetic evidences.

Pharmacological characterization of the nociceptin/orphanin FQ receptor antagonist SB-612111 [(-)-cis-1-methyl-7-[[4-(2,6-dichlorophenyl)piperidin-1-yl]methyl]-6,7,8,9-tetrahydro-5H-benzocyclohepten-5-ol]: in vivo studies.

Altered anxiety-related behavior in nociceptin/orphanin FQ receptor gene knockout mice.

Functional antagonism between nociceptin/orphanin FQ (N/OFQ) and corticotropin-releasing factor (CRF) in the rat brain: evidence for involvement of the bed nucleus of the stria terminalis.

In vitro and in vivo pharmacological characterization of the neuropeptide s receptor antagonist [D-Cys(tBu)5]neuropeptide S.

Fgf-2 overexpression increases excitability and seizure susceptibility but decreases seizure-induced cell loss.

Localized delivery of fibroblast growth factor-2 and brain-derived neurotrophic factor reduces spontaneous seizures in an epilepsy model.

Brain interstitial nociceptin/orphanin FQ levels are elevated in Parkinson's disease.

Are the neurotrophic factors a suitable therapeutic target for the prevention of epileptogenesis?

Hippocampal FGF-2 and BDNF overexpression attenuates epileptogenesis-associated neuroinflammation and reduces spontaneous recurrent seizures.

Localized overexpression of FGF-2 and BDNF in hippocampus reduces mossy fiber sprouting and spontaneous seizures up to 4 weeks after pilocarpine-induced status epilepticus.

Bystander effect on brain tissue of mesoangioblasts producing neurotrophins.

Increased excitability in tat-transgenic mice: role of tat in HIV-related neurological disorders.

Implication of fibroblast growth factors in epileptogenesis-associated circuit rearrangements.

Impairment of GABA release in the hippocampus at the time of the first spontaneous seizure in the pilocarpine model of temporal lobe epilepsy.

Identification of miRNAs differentially expressed in human epilepsy with or without granule cell pathology.

Increased extracellular levels of glutamate in the hippocampus of chronically epileptic rats.

MicroRNA profiles in hippocampal granule cells and plasma of rats with pilocarpine-induced epilepsy--comparison with human epileptic samples.

Effects of [Nphe1, Arg14, Lys15] N/OFQ-NH2 (UFP-101), a potent NOP receptor antagonist, on molecular, cellular and behavioural alterations associated with chronic mild stress.

Deletion of the Virion Host Shut-off Gene Enhances Neuronal-Selective Transgene Expression from an HSV Vector Lacking Functional IE Genes.

A potential reservoir of immature dopaminergic replacement neurons in the adult mammalian olfactory bulb.